In January 1997, 62 subjects who had been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy (hay fever) sleep aid symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the b12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the 5. improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 a bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 from the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. all subjects also received c and b oral multivitamins for 21 days. twice daily aid subjects maintained a nine-week diary on sleep aid sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) aid use. in the post-treatment period, the active group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). the results yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and 9. the results tend to replicate those of the studies on injectable cyanocobalamin.10

with sleep no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in oregon, washington and idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 patients gave blood serum samples prior aid to the treatment in 1995 and one year later in 1996. they were immunoassayed for specific ige antibodies using a chemi-luminescent technique. statistician bradley rosebrook ran t-tests comparing average baseline sleep ige levels to one-year. for the seasonal allergens reported, the active group (n=27) had on average a greater reduction in ige than the placebo group (n=34) for aid 13 out of 16 allergens.8

“the high cd4/cd8 ratio and suppressed nk cell activity were improved by methyl-b12 treatment.” the japanese researchers state: “we conclude that vitamin b12 acts as an immunomodulator for cellular immunity.”11 b12 was used successfully in the treatment of ige-mediated skin disorders. the german researchers conclude that b12 (cobalamin) when applied to the skin one or more times per day exhibited “...excellent results in topical treatment of skin disorders and in particular of inflammatory and hyperproliferative skin ailments and/or cutaneous manifestations of illness which are immunologic in origin, e.g. psoriasis, atopic dermatitis, contact dermatitis, and other eczematous dermatitises...”12 click here for allergy medication online.